The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non-24-hour Sleep-wake Disorder Treatment Market Research Report 2024
Synopsis
Non-24-hour sleep-wake disorder (N24) is a circadian rhythm sleep disorder in which an individual's biological clock fails to synchronize to a 24-hour day. Instead of sleeping at roughly the same time every day, someone with N24 will typically find their sleep time gradually delaying by minutes to hours every day.
Global Non-24-hour Sleep-wake Disorder Treatment market is projected to reach US$ 726.1 million in 2029, increasing from US$ 480 million in 2022, with the CAGR of 6.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-24-hour Sleep-wake Disorder Treatment market research.
Key companies engaged in the Non-24-hour Sleep-wake Disorder Treatment industry include Teva, Mylan, Nature’s Bounty, Otsuka Pharma (Pharmavite), Boiron, Miers Laboratories, Genexa, Homeocan and Clinigen Group, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Non-24-hour Sleep-wake Disorder Treatment were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Non-24-hour Sleep-wake Disorder Treatment market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Non-24-hour Sleep-wake Disorder Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Teva
Mylan
Nature’s Bounty
Otsuka Pharma (Pharmavite)
Boiron
Miers Laboratories
Genexa
Homeocan
Clinigen Group
Vanda Pharma
Segment by Type
Prescription Drugs
OTC
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Non-24-hour Sleep-wake Disorder Treatment report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Non-24-hour sleep-wake disorder (N24) is a circadian rhythm sleep disorder in which an individual's biological clock fails to synchronize to a 24-hour day. Instead of sleeping at roughly the same time every day, someone with N24 will typically find their sleep time gradually delaying by minutes to hours every day.
Global Non-24-hour Sleep-wake Disorder Treatment market is projected to reach US$ 726.1 million in 2029, increasing from US$ 480 million in 2022, with the CAGR of 6.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-24-hour Sleep-wake Disorder Treatment market research.
Key companies engaged in the Non-24-hour Sleep-wake Disorder Treatment industry include Teva, Mylan, Nature’s Bounty, Otsuka Pharma (Pharmavite), Boiron, Miers Laboratories, Genexa, Homeocan and Clinigen Group, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Non-24-hour Sleep-wake Disorder Treatment were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Non-24-hour Sleep-wake Disorder Treatment market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Non-24-hour Sleep-wake Disorder Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Teva
Mylan
Nature’s Bounty
Otsuka Pharma (Pharmavite)
Boiron
Miers Laboratories
Genexa
Homeocan
Clinigen Group
Vanda Pharma
Segment by Type
Prescription Drugs
OTC
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Non-24-hour Sleep-wake Disorder Treatment report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-24-hour Sleep-wake Disorder Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Prescription Drugs
1.2.3 OTC
1.3 Market by Application
1.3.1 Global Non-24-hour Sleep-wake Disorder Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-24-hour Sleep-wake Disorder Treatment Market Perspective (2018-2029)
2.2 Non-24-hour Sleep-wake Disorder Treatment Growth Trends by Region
2.2.1 Global Non-24-hour Sleep-wake Disorder Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Non-24-hour Sleep-wake Disorder Treatment Historic Market Size by Region (2018-2023)
2.2.3 Non-24-hour Sleep-wake Disorder Treatment Forecasted Market Size by Region (2024-2029)
2.3 Non-24-hour Sleep-wake Disorder Treatment Market Dynamics
2.3.1 Non-24-hour Sleep-wake Disorder Treatment Industry Trends
2.3.2 Non-24-hour Sleep-wake Disorder Treatment Market Drivers
2.3.3 Non-24-hour Sleep-wake Disorder Treatment Market Challenges
2.3.4 Non-24-hour Sleep-wake Disorder Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-24-hour Sleep-wake Disorder Treatment Players by Revenue
3.1.1 Global Top Non-24-hour Sleep-wake Disorder Treatment Players by Revenue (2018-2023)
3.1.2 Global Non-24-hour Sleep-wake Disorder Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Non-24-hour Sleep-wake Disorder Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-24-hour Sleep-wake Disorder Treatment Revenue
3.4 Global Non-24-hour Sleep-wake Disorder Treatment Market Concentration Ratio
3.4.1 Global Non-24-hour Sleep-wake Disorder Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-24-hour Sleep-wake Disorder Treatment Revenue in 2022
3.5 Non-24-hour Sleep-wake Disorder Treatment Key Players Head office and Area Served
3.6 Key Players Non-24-hour Sleep-wake Disorder Treatment Product Solution and Service
3.7 Date of Enter into Non-24-hour Sleep-wake Disorder Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-24-hour Sleep-wake Disorder Treatment Breakdown Data by Type
4.1 Global Non-24-hour Sleep-wake Disorder Treatment Historic Market Size by Type (2018-2023)
4.2 Global Non-24-hour Sleep-wake Disorder Treatment Forecasted Market Size by Type (2024-2029)
5 Non-24-hour Sleep-wake Disorder Treatment Breakdown Data by Application
5.1 Global Non-24-hour Sleep-wake Disorder Treatment Historic Market Size by Application (2018-2023)
5.2 Global Non-24-hour Sleep-wake Disorder Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Non-24-hour Sleep-wake Disorder Treatment Market Size (2018-2029)
6.2 North America Non-24-hour Sleep-wake Disorder Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Non-24-hour Sleep-wake Disorder Treatment Market Size by Country (2018-2023)
6.4 North America Non-24-hour Sleep-wake Disorder Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-24-hour Sleep-wake Disorder Treatment Market Size (2018-2029)
7.2 Europe Non-24-hour Sleep-wake Disorder Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Non-24-hour Sleep-wake Disorder Treatment Market Size by Country (2018-2023)
7.4 Europe Non-24-hour Sleep-wake Disorder Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-24-hour Sleep-wake Disorder Treatment Market Size (2018-2029)
8.2 Asia-Pacific Non-24-hour Sleep-wake Disorder Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Non-24-hour Sleep-wake Disorder Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-24-hour Sleep-wake Disorder Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-24-hour Sleep-wake Disorder Treatment Market Size (2018-2029)
9.2 Latin America Non-24-hour Sleep-wake Disorder Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Non-24-hour Sleep-wake Disorder Treatment Market Size by Country (2018-2023)
9.4 Latin America Non-24-hour Sleep-wake Disorder Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-24-hour Sleep-wake Disorder Treatment Market Size (2018-2029)
10.2 Middle East & Africa Non-24-hour Sleep-wake Disorder Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Non-24-hour Sleep-wake Disorder Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-24-hour Sleep-wake Disorder Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Detail
11.1.2 Teva Business Overview
11.1.3 Teva Non-24-hour Sleep-wake Disorder Treatment Introduction
11.1.4 Teva Revenue in Non-24-hour Sleep-wake Disorder Treatment Business (2018-2023)
11.1.5 Teva Recent Development
11.2 Mylan
11.2.1 Mylan Company Detail
11.2.2 Mylan Business Overview
11.2.3 Mylan Non-24-hour Sleep-wake Disorder Treatment Introduction
11.2.4 Mylan Revenue in Non-24-hour Sleep-wake Disorder Treatment Business (2018-2023)
11.2.5 Mylan Recent Development
11.3 Nature’s Bounty
11.3.1 Nature’s Bounty Company Detail
11.3.2 Nature’s Bounty Business Overview
11.3.3 Nature’s Bounty Non-24-hour Sleep-wake Disorder Treatment Introduction
11.3.4 Nature’s Bounty Revenue in Non-24-hour Sleep-wake Disorder Treatment Business (2018-2023)
11.3.5 Nature’s Bounty Recent Development
11.4 Otsuka Pharma (Pharmavite)
11.4.1 Otsuka Pharma (Pharmavite) Company Detail
11.4.2 Otsuka Pharma (Pharmavite) Business Overview
11.4.3 Otsuka Pharma (Pharmavite) Non-24-hour Sleep-wake Disorder Treatment Introduction
11.4.4 Otsuka Pharma (Pharmavite) Revenue in Non-24-hour Sleep-wake Disorder Treatment Business (2018-2023)
11.4.5 Otsuka Pharma (Pharmavite) Recent Development
11.5 Boiron
11.5.1 Boiron Company Detail
11.5.2 Boiron Business Overview
11.5.3 Boiron Non-24-hour Sleep-wake Disorder Treatment Introduction
11.5.4 Boiron Revenue in Non-24-hour Sleep-wake Disorder Treatment Business (2018-2023)
11.5.5 Boiron Recent Development
11.6 Miers Laboratories
11.6.1 Miers Laboratories Company Detail
11.6.2 Miers Laboratories Business Overview
11.6.3 Miers Laboratories Non-24-hour Sleep-wake Disorder Treatment Introduction
11.6.4 Miers Laboratories Revenue in Non-24-hour Sleep-wake Disorder Treatment Business (2018-2023)
11.6.5 Miers Laboratories Recent Development
11.7 Genexa
11.7.1 Genexa Company Detail
11.7.2 Genexa Business Overview
11.7.3 Genexa Non-24-hour Sleep-wake Disorder Treatment Introduction
11.7.4 Genexa Revenue in Non-24-hour Sleep-wake Disorder Treatment Business (2018-2023)
11.7.5 Genexa Recent Development
11.8 Homeocan
11.8.1 Homeocan Company Detail
11.8.2 Homeocan Business Overview
11.8.3 Homeocan Non-24-hour Sleep-wake Disorder Treatment Introduction
11.8.4 Homeocan Revenue in Non-24-hour Sleep-wake Disorder Treatment Business (2018-2023)
11.8.5 Homeocan Recent Development
11.9 Clinigen Group
11.9.1 Clinigen Group Company Detail
11.9.2 Clinigen Group Business Overview
11.9.3 Clinigen Group Non-24-hour Sleep-wake Disorder Treatment Introduction
11.9.4 Clinigen Group Revenue in Non-24-hour Sleep-wake Disorder Treatment Business (2018-2023)
11.9.5 Clinigen Group Recent Development
11.10 Vanda Pharma
11.10.1 Vanda Pharma Company Detail
11.10.2 Vanda Pharma Business Overview
11.10.3 Vanda Pharma Non-24-hour Sleep-wake Disorder Treatment Introduction
11.10.4 Vanda Pharma Revenue in Non-24-hour Sleep-wake Disorder Treatment Business (2018-2023)
11.10.5 Vanda Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
